On a sunny day in July, while other Bay Area kids were playing at camps or water parks, 8-year-old Charlotte O’Neill was leaning back in a reclining chair in a small, carpeted San Jose office room.

Efforts have been made in recent years to clarify the value of exercise as an adjunctive or independent treatment for major ...

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation. Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Seasonal affective disorder ... % of people get the "winter blues," mild depression from being cooped up indoors, according ...